[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,49,76,100,121,138,158,174,198,219,240,264,286,310,330,351,375,403,429,450,472,503,522,550,578],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054078","acupuncture-versus-sham-acupuncture-for-tinnitus-100054078",false,"NCT07700069","Acupuncture Versus Sham Acupuncture for Tinnitus","Efficacy and Safety of Acupuncture Versus Sham Acupuncture in the Treatment of Tinnitus: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Tinnitus as the primary complaint, meeting the diagnostic criteria for subjective idiopathic tinnitus.\n2. Tinnitus duration of at least 6 months.\n3. Patent external auditory canal and intact tympanic membrane.\n4. Bilateral pure tone average no greater than 80 decibels hearing level (dB HL).\n5. No contraindications to MRI or MEG scanning, such as claustrophobia or metallic implants.\n6. Age 18 to 80 years.\n7. Right-handed.\n8. Baseline Tinnitus Handicap Inventory score of 38 or higher.\n9. Able to understand and complete examinations, assessments, and treatment procedures under physician guidance.\n10. Willing to participate and able to provide written informed consent before treatment.\n\nExclusion Criteria:\n\n1. Inner ear or auditory nerve disorders, including sudden sensorineural hearing loss, Meniere disease, otosclerosis, or acoustic neuroma.\n2. External or middle ear diseases, including otitis externa, foreign body in the external auditory canal, eczema of the external auditory canal, cerumen impaction, acute or chronic otitis media with effusion, or acute or chronic suppurative otitis media.\n3. Non-otogenic tinnitus caused by acute or chronic systemic diseases involving hematologic, endocrine, renal, or other major organ systems.\n4. Objective tinnitus, including myogenic, vascular, or patulous eustachian tube-related tinnitus.\n5. Cognitive impairment or tinnitus caused by other neurological diseases, including stroke, epilepsy, traumatic brain injury, severe headache history, severe central ischemia, brain tumor, neurasthenia, or post-neurosurgical tinnitus.\n6. Severe cardiovascular or cerebrovascular disease, intracranial space-occupying disease, tumor, or severe pulmonary, hepatic, renal, or hematopoietic disease.\n7. Pregnancy or lactation.\n8. Psychiatric disease, impaired consciousness, or inability to cooperate with examinations or treatment.\n9. Participation in another conflicting clinical trial within 6 months before enrollment or currently participating in another conflicting clinical trial.","ALL","18 Years","80 Years",{"count":21,"type":22},226,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter, randomized, sham-controlled clinical trial will evaluate the efficacy and safety of acupuncture for patients with subjective idiopathic tinnitus. A total of 226 eligible participants will be randomly assigned to receive either acupuncture or sham acupuncture. Both groups will receive treatment for 5 weeks. The primary outcome is the change in Tinnitus Handicap Inventory score from baseline to Week 5. Secondary outcomes include tinnitus loudness, tinnitus severity, sleep quality, anxiety, depression, audiological assessments, and adverse events. Exploratory neuroimaging outcomes include functional magnetic resonance imaging and magnetoencephalography measures.",[28],"Tinnitus",[30,31,32,33,34,35],"Subjective Idiopathic Tinnitus","Acupuncture","Sham Acupuncture","Randomized Controlled Trial","Tinnitus Handicap Inventory","Magnetoencephalography","NOT_YET_RECRUITING","2026-07-07",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":22},"2026-07-10",{"date":44,"type":22},"2027-03-31",{"name":46,"class":47},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER",3,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100645330","efficacy-of-lymphatic-venous-anastomosis-plus-donepezil-versus-donepezil-alone-for-alzheimers-disease-100645330","NCT07680660","Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease","A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Cervical Lymph Vessel\u002FNode-venous Anastomosis Combined With Donepezil Versus Donepezil Alone in the Treatment of Alzheimer's Disease","Inclusion Criteria\n\n1. The patient or guardian signs the informed consent form;\n2. Age 50-80 years (≥50 years, ≤80 years), male or female;\n3. The first diagnosis is Alzheimer's disease with dementia;\n4. MMSE score ≤24;\n5. Positive β-amyloid protein PET imaging findings;\n6. HAMD score ≤17;\n7. Hachinski score ≤7;\n8. No AD-related drug treatment has been received within the past 1 month;\n9. ASA grade 1-3 (≥ grade 1, ≤ grade 3).\n10. CDR-SB score of 9.5-15.5\n\nExclusion Criteria\n\n1. Presence of contraindications to MRI, ICG angiography, or PET scan;\n2. Presence of contraindications to lumbar puncture;\n3. Severe heart disease or unstable hemodynamic status;\n4. Severe lung disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or acute inflammation within 3 months;\n5. Hepatic insufficiency, AST or ALT \\>3 times the upper limit of normal;\n6. Renal insufficiency, GFR \\\u003C60 mL\u002Fmin or need for blood purification treatment;\n7. MRI indicates active or acute intracranial lesions, including intracranial infection, space-occupying lesions, major hemorrhage, and ≥4 lobar microbleeds, etc.;\n8. History of cerebral hemorrhage or cerebral infarction with severe residual neurological dysfunction;\n9. Blood diseases, bleeding\u002Fcoagulation disorders, coagulation dysfunction;\n10. Abnormal thyroid function;\n11. Moderate or severe stenosis of intracranial or cervical vessels with severe residual neurological dysfunction;\n12. Severe hypertension not effectively controlled, systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;\n13. The disease requires systemic use of steroids;\n14. Drug addiction (including alcohol, narcotics, and alcohol dependence);\n15. Severe infectious diseases, including HIV positivity, severe infection, etc.;\n16. Severe psychiatric disease or potential suicide risk;\n17. Within 3 years after radical surgery for malignant tumor;\n18. Participation in other interventional clinical trials within the past three months;\n19. In the physician's judgment, poor compliance, inability to complete, or unwillingness to cooperate with regular postoperative follow-up;\n20. Other circumstances that the physician considers unsuitable for this clinical trial.\n21. Anti-Aβ monoclonal antibody treatment has been received within half a year","50 Years",{"count":58,"type":22},216,[25],"This study employed a multicenter, randomized controlled trial (RCT) design to evaluate the efficacy and safety of deep cervical lymphatic\u002Flymph node-venous anastomosis combined with oral donepezil compared to donepezil monotherapy in patients with Alzheimer's disease and moderate dementia. Participants were randomized using a central randomization system with stratified block design, with the study center and age group (50-64 years, 65-80 years) as stratification factors. While study participants and surgical investigators could not be blinded due to the nature of the intervention, efficacy assessors and imaging specialists remained blinded to ensure the objectivity and reliability of the findings. The intervention group received deep cervical lymphatic\u002Flymph node-venous anastomosis (detailed surgical procedure is specified in the protocol) in combination with oral donepezil (5-10 mg\u002Fday), while the control group received oral donepezil alone. The total treatment and follow-up period was 18 months, with assessments conducted at baseline, 1 week, 1, 3, 6, 12, and 18 months post-operation. These included neuropsychological evaluations (MMSE, MoCA, CDR, BADL, IADL, NPI, AES), neuroimaging (MRI, PET, ultrasound), fluid biomarker analyses (CSF and blood levels of Aβ, Tau, neuroinflammatory factors, etc.), and safety monitoring. The primary efficacy endpoint was the change in CDR-SB score at 12 months post-treatment. Secondary endpoints included changes in multiple cognitive scales, neuroimaging metrics, and biomarkers at 18 months. Safety indicators encompassed adverse event recording, vital signs, and laboratory tests.",[62],"Alzheimer s Disease",[64,65,66],"cervical lymph vessel\u002Fnode-venous anastomosis","LVA","Alzheimer","2026-06-25",{"date":69,"type":40},"2026-07-02",{"date":71,"type":22},"2026-07-15",{"date":73,"type":22},"2029-03-31",{"name":46,"class":47},1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":75},"100644407","classify-omm-multicenter-rare-disease-cohort-for-t-stage-reclassification-and-molecular-subtyping-based-precision-therapy-in-oral-mucosal-melanoma-100644407","NCT07662694","CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma","CLASSIFY-OMM","Inclusion Criteria:\n\n* Histopathologically confirmed primary oral mucosal melanoma (WHO criteria);\n\nPrimary site: oral mucosa (palate, gingiva, sublingual, buccal, hard palate, floor of mouth);\n\nReceiving or planning standard treatment (surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy);\n\nAge ≥18 years, any sex;\n\nComplete clinical data with pathology, imaging, and records (retrospective) OR willingness for long-term follow-up (prospective);\n\nSigned informed consent (prospective) or data meeting ethical waiver (retrospective).\n\nExclusion Criteria:\n\n* Primary melanoma originating from skin, eye, esophagus, or other non-oral mucosal sites;\n\nSecondary\u002Fmetastatic oral mucosal melanoma (primary not in oral cavity);\n\nUnavailable key clinical information (surgical records, pathology, imaging);\n\nPrior or concurrent other malignancy interfering with prognosis;\n\nSevere mental\u002Fcognitive disorders or poor compliance;\n\nSevere comorbidities (heart failure, liver\u002Frenal failure) affecting treatment or survival analysis;\n\nPatient refusal or withdrawal of informed consent.",{"count":84,"type":22},1100,"OBSERVATIONAL","This bidirectional cohort study (retrospective + prospective) focuses on three key challenges in oral mucosal melanoma (OMM): clinical staging based on depth of invasion (DOI), molecular subtyping, and precision therapy. By integrating DOI-driven T-stage reclassification, genomic profiling, and longitudinal follow-up, we aim to build a population-specific, high-quality evidence resource to support refined staging, CDK4-targeted treatment, and prognostic modeling for Chinese OMM patients.",[88,89],"Mucosal Melanoma of the Head and Neck","Oral Melanoma",[91],"Mucosal Melanoma","2026-06-17",{"date":94,"type":40},"2026-06-23",{"date":96,"type":22},"2026-07-01",{"date":98,"type":22},"2029-12-30",{"name":46,"class":47},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":75},"100644390","phase-1-camrelizumab-with-famitinib-for-patients-with-rare-head-and-neck-malignancies-100644390","NCT07662681","Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies","A Prospective, Multi-Cohort Study of Camrelizumab in Combination With Famitinib for the Treatment of Patients With Rare Head and Neck Malignancies","Inclusion Criteria:\n\n* Age ≥18 years; Histologically or cytologically confirmed unresectable or recurrent\u002Fmetastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland carcinoma (non-adenoid cystic carcinoma) with no indication for curative treatment; Salivary gland tumors must be negative for both HER2 and AR, as determined by IHC; ECOG PS of 0-1; At least one measurable lesion according to RECIST v1.1 criteria; No prior PD-1 inhibitor therapy; Received ≤1 prior systemic therapy regimen; Adequate organ function, as defined by the following laboratory values: Organ Laboratory Value Hematology Absolute neutrophil count ≥1500\u002FμL (1.5×10\\^9\u002FL) Platelets ≥100,000\u002FμL (100×10\\^9\u002FL) Hemoglobin ≥9 g\u002FdL (90 g\u002FL) or ≥5.6 mmol\u002FL Renal Creatinine or Creatinine clearance Creatinine ≤1.5×ULN; if creatinine \\>1.5×ULN, then creatinine clearance ≥60 mL\u002Fmin Hepatic Total bilirubin ≤1.5×ULN AST and ALT ≤2.5×ULN, or ≤5×ULN in the presence of liver metastases Coagulation INR or PT ≤1.5×ULN; for patients receiving anticoagulants, PT or PTT must be within the therapeutic range of the anticoagulant being used Female subjects must have a negative pregnancy test within 2 weeks prior to the start of study treatment and must not be breastfeeding. Female subjects must agree to use highly effective contraceptive measures during the study and for 6 months after the last dose of study drug. Male subjects must agree to use highly effective contraceptive measures during the study and for 6 months after the last dose of study drug; Subject voluntarily agrees to participate in the study, provides written informed consent, and is able to comply with the protocol-specified visits and related procedures.\n\nExclusion Criteria:\n\n* Radiotherapy or other local therapy (e.g., surgery) within 2 weeks prior to enrollment, or failure to recover from adverse events of prior therapy (i.e., to ≤Grade 1 or baseline); Participation in a clinical trial within 4 weeks prior to enrollment; Poorly controlled cardiac symptoms or diseases, including: (1) NYHA Class II or higher heart failure or LVEF \\\u003C50% on echocardiography; (2) unstable angina; (3) myocardial infarction within 1 year prior to study treatment; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; (5) QTc \\>450 ms (males) or QTc \\>470 ms (females) (QTc interval calculated using the Fridericia formula; if QTc is abnormal, three consecutive measurements at 2-minute intervals may be taken and averaged).\n\nHypertension that cannot be controlled to within the normal range with antihypertensive medication (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, based on the average of ≥2 BP readings); use of antihypertensive therapy to achieve these parameters is permitted. History of hypertensive crisis or hypertensive encephalopathy.\n\nPresence of multiple factors affecting oral drug absorption (e.g., inability to swallow, nausea and vomiting, chronic diarrhea, intestinal obstruction, etc.).\n\nThrombotic or embolic events within 6 months prior to study treatment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.\n\nCurrent interstitial pneumonitis or interstitial lung disease, or a history of interstitial pneumonitis or interstitial lung disease requiring corticosteroid therapy, or other conditions such as pulmonary fibrosis, organizing pneumonia, pneumoconiosis, drug-induced pneumonitis, or idiopathic pneumonitis that may interfere with the assessment and management of immune-related pulmonary toxicity, or evidence of active pneumonitis or severely impaired pulmonary function on chest CT at screening. Prior radiation pneumonitis in the radiation field is permitted; active tuberculosis.\n\nInvestigator-assessed life expectancy of less than 3 months, or rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain, etc.); Abnormal coagulation function (INR \\>1.5×ULN, APTT \\>1.5×ULN) or bleeding tendency; Diagnosis of immunodeficiency within 7 days prior to enrollment, or receiving systemic corticosteroid therapy or other forms of immunosuppressive therapy.\n\nDiagnosis of other malignancies within 5 years prior to enrollment, except for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, or other cured tumors that the investigator considers acceptable for exclusion.\n\nKnown active central nervous system metastases; Tumor invasion of major blood vessels or tumor ulceration with bleeding, as judged by the investigator; Active autoimmune disease requiring systemic therapy within 2 years prior to enrollment; History of allogeneic tissue transplantation or solid organ transplantation; Active infection requiring systemic therapy; Psychiatric illness or substance abuse that would interfere with trial compliance or cooperation; Positive serology for HIV or a history of HIV infection; Active HBV or HCV infection; Receipt of a live vaccine within 30 days prior to the start of the trial. Other factors, such as medical history, that in the investigator's assessment could compromise subject safety or affect trial evaluations.",{"count":108,"type":22},40,[110,111],"PHASE1","PHASE2","This is a prospective, multicenter, multi-cohort, Phase II clinical trial enrolling patients with unresectable, recurrent, or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland malignancies (excluding adenoid cystic carcinoma) who have not previously received PD-1 inhibitor therapy. The planned sample size is 10 subjects per cohort, for a total of 40 subjects. Investigators may adjust the cohort sample sizes based on actual enrollment. Potentially eligible subjects will be screened within 4 weeks prior to the first dose to assess their eligibility for study entry. Subjects confirmed by the investigator to meet all inclusion criteria and none of the exclusion criteria will receive the investigational medicinal products as per the study design and undergo efficacy and safety assessments. This trial will consist of three periods: Screening\u002FBaseline Period, Treatment Period, and Follow-up Period. The study procedures include: Screening Period: From the signing of the informed consent form up to 28 days prior to the first dose; Treatment Period: Treatment discontinuation is defined as the cessation of treatment for any reason, such as disease progression or intolerance, or premature withdrawal for any reason; Follow-up Period: Following the subject's last dose, safety follow-up will be initiated to monitor the resolution of adverse events. The first safety follow-up visit will occur 30 ± 7 days after the last study dose (calculated based on the later date of 30 days post the last dose of either camrelizumab or famitinib). Subjects are required to return to the study center for this safety follow-up, regardless of whether they have initiated new antineoplastic therapy. The subsequent two safety visits (60 ± 7 days and 90 ± 7 days after the last dose) may be conducted via telephone. After study discontinuation, survival follow-up will be conducted every 3 months to monitor survival status and subsequent antineoplastic treatments. The dosing regimen is as follows: camrelizumab 200 mg, IV, on Day 1, Q3W; famitinib 10 mg, PO, QD, Q3W, with 21 days constituting one treatment cycle. Study drugs should be administered at approximately the same time each day. If a patient vomits or misses a dose, no replacement dose should be taken on that day, and the next scheduled dose should be taken as usual. Subjects will continue treatment with camrelizumab and famitinib until discontinuation criteria are met. Clinical tumor imaging assessments will be performed every 2 cycles according to RECIST v1.1 (Appendix IV). Additionally, on Day 1 of each treatment cycle, clinically required assessments must be completed, including vital signs, physical examination, complete blood count, urinalysis, fecal occult blood test, hepatic and renal function tests, serum electrolytes, serum proteins, coagulation profile, serum tumor markers, thyroid function, electrocardiogram (ECG), and ECOG performance status score (specific assessments for each visit are detailed in the Schedule of Assessments). Hepatitis virus carriers will also require viral load monitoring every 2 to 4 treatment cycles.",[114],"Head and Neck Cancer","RECRUITING",{"date":94,"type":40},{"date":96,"type":22},{"date":119,"type":22},"2029-07-01",{"name":46,"class":47},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":137,"locationsCount":75},"100644313","phase-2-efficacy-and-safety-of-paclitaxel-polymeric-micelles-in-patients-with-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-100644313","NCT07662746","Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma","Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Single-Arm, Exploratory Phase II Clinical Study","Inclusion Criteria:\n\n* Age ≥18 and ≤75 years, male or female; Histologically or cytologically confirmed head and neck squamous cell carcinoma; Prior first-line systemic therapy (including chemotherapy, targeted therapy, and immunotherapy) with disease progression or judged by the clinician to no longer derive clinical benefit; ECOG performance status score of 0-2 and a life expectancy of at least 3 months; At least one measurable lesion on imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 3);\n\nAdequate major organ function, with subjects meeting the following laboratory parameters:\n\nComplete blood count meeting the following criteria (no blood transfusion, blood products, granulocyte colony-stimulating factor, or other hematopoietic growth factors within 7 days prior to the test): WBC ≥3.0×10\\^9\u002FL, ANC ≥1.5×10\\^9\u002FL, platelets ≥100×10\\^9\u002FL, hemoglobin ≥90 g\u002FL; Blood biochemistry meeting the following criteria: total bilirubin ≤1.5×ULN, AST, ALT, or ALP ≤2.5×ULN (for subjects with liver metastases, ALT, AST, or ALP ≤5×ULN is permitted; for subjects with bone metastases, ALP ≤10×ULN is permitted); serum creatinine ≤1.5×ULN and creatinine clearance (calculated using the Cockcroft-Gault formula, Appendix 4) ≥50 mL\u002Fmin; Adequate coagulation function, defined as INR ≤1.5×ULN and PT or APTT ≤1.5×ULN; Subjects of childbearing potential must agree to use highly effective contraceptive measures during the trial. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of chemotherapy; Good compliance, able to undergo treatment and follow-up, and willing to comply with the study requirements; voluntary signing of the informed consent form.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to any study treatment or any excipient; Presence of uncontrolled serious medical conditions, such as severe comorbidities including severe cardiac disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.; Other malignancies within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, or ductal carcinoma in situ after radical surgery; Requirement for concomitant use of other antineoplastic drugs; Receipt of any other investigational drug or participation in another interventional clinical trial within 30 days prior to screening; History of psychotropic substance abuse with inability to abstain, or presence of psychiatric disorders; Pregnant or breastfeeding women; Patients deemed unsuitable for enrollment by the investigator.","75 Years",{"count":130,"type":22},29,[111],"Paclitaxel polymeric micelles 300 mg\u002Fm², IV infusion over ≥3 hours, Day 1; carboplatin AUC 5, IV infusion over 1 hour, Day 1. Each cycle consists of 3 weeks (Q3W), for a total of 3 cycles. (Efficacy assessment will be performed after 3 cycles of treatment. In the absence of disease progression, treatment may be continued until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other antineoplastic therapy, death, or other protocol-specified criteria for treatment discontinuation, whichever occurs first.)",[114],{"date":94,"type":40},{"date":96,"type":22},{"date":119,"type":22},{"name":46,"class":47},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":75},"100599724","phase-2-sacituzumab-tirumotecan-and-toripalimab-in-the-first-line-treatment-of-hnscc-100599724","NCT07088211","Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC","Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma Patients With trop2 and CPS Positive: A Prospective, Single Arm, Phase II Trial","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender; Histologically or cytologically confirmed newly diagnosed locally advanced, recurrent or metastatic head and neck squamous cell carcinoma (primary tumor sites include oropharynx, oral cavity, hypopharynx, and larynx) that cannot be cured by local treatment. No anti-tumor systemic treatment has been received in the recurrent or metastatic stage (systemic treatment as part of local advanced tumor treatment is allowed, provided that more than 6 months have passed from the end of treatment to the signing of informed consent); ECOG performance status of 0 or 1; Expected survival period ≥ 12 weeks; At least one measurable lesion according to RECIST 1.1 criteria. Lesions that have received previous radiotherapy can be used as measurable lesions if disease progression occurs; Availability of tumor tissue for PD-L1 detection (paraffin-embedded specimens within 2 years or fresh tumor tissue); PD-L1 CPS ≥ 1 and positive trop2 expression, detected by immunohistochemistry; For oropharyngeal cancer patients, P16 detection status, detected by IHC;\n\nNormal function of major organs within 2 weeks before treatment, meeting the following criteria:\n\nBone marrow function: Hemoglobin ≥ 100g\u002FL, white blood cell count ≥ 4.0×10\\^9\u002FL or neutrophil count ≥ 2.0×10\\^9\u002FL, platelet count ≥ 100×10\\^9\u002FL without blood transfusion or colony-stimulating factor support; Liver function: Serum total bilirubin level ≤ 1.5 times the upper limit of normal, aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 times the upper limit of normal; Renal function: Serum creatinine level \\\u003C 1.5 times the upper limit of normal or creatinine clearance rate ≥ 60ml\u002Fmin, blood urea nitrogen ≤ 200mg\u002FL; Urinary protein \\\u003C +; if urinary protein is +, the 24-hour total protein must be \\\u003C 500mg; Blood glucose: Within the normal range and\u002For for diabetic patients, blood glucose is controlled in a stable state during treatment; Cardiac function: No myocardial infarction within 1 year; no unstable angina; no symptomatic severe arrhythmia; no cardiac insufficiency; For women of childbearing age, serum pregnancy test results must be negative within 7 days before the first administration of the trial drug; males with reproductive capacity or females with the possibility of pregnancy must use highly effective contraceptive methods (such as oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides) throughout the trial, and continue contraception for 12 months after the end of treatment; Subjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up; Patients whom doctors believe can benefit from the treatment.\n\nExclusion Criteria:\n\n* Disease progression occurring within 6 months after systemic treatment for locally advanced head and neck squamous cell carcinoma; A history of primary nasopharyngeal carcinoma; Central nervous system metastasis and\u002For carcinomatous meningitis; Patients with hearing loss ≥ grade 2 or neuropathy ≥ grade 2 who are currently receiving anti-tumor treatment; Patients who have participated in or are participating in other drug\u002Ftherapy clinical trials within 4 weeks before the first administration of the study drug; Patients who have received hematopoietic stimulating factors (such as granulocyte colony-stimulating factor (G-CSF), erythropoietin, etc.) within 1 week before the first administration of the study drug; Positive results for HIV antibody or Treponema pallidum antibody tests;\n\nPatients with active hepatitis B or hepatitis C:\n\nFor those with positive HBsAg or HBcAb, additional HBV DNA testing is required (if the result is higher than the upper limit of the normal range); For those with positive HCV antibody test results, additional HCV RNA testing is required (if the result is higher than the upper limit of the normal range); Active lung diseases (interstitial pneumonia, pneumonia, obstructive pulmonary disease, asthma) or a history of active pulmonary tuberculosis; Patients with any active autoimmune disease or a history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; vitiligo that does not require systemic treatment can be included; asthma that has been completely relieved in childhood and requires no intervention in adulthood can be included; asthma in patients requiring medical intervention with bronchodilators cannot be included); Patients who are using immunosuppressants or systemic hormone therapy for the purpose of immunosuppression (dose \\> 10mg\u002Fday prednisone or other hormones with equivalent efficacy) and continue to use them within 2 weeks before enrollment;\n\nHaving any uncontrollable clinical problems, including but not limited to:\n\nPersistent or active (severe) infections; Poorly controlled diabetes; Cardiac diseases (New York Heart Association class III\u002FIV congestive heart failure or heart block); The following conditions occurring within 6 months before the first dose: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina pectoris; percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, cerebral embolism.\n\nLarge amounts of pleural effusion or ascites with clinical symptoms requiring symptomatic treatment; Patients who received cytochrome P450 3A4 (CYP3A4) inhibitors within one week before screening; A history of stem cell transplantation or organ transplantation; Patients with a history of psychoactive substance abuse who are unable to abstain or a history of mental disorders; Other severe, acute or chronic medical diseases or laboratory test abnormalities that the researcher judges may increase the risks related to study participation or may interfere with the interpretation of study results; Patients judged by the researcher to have poor compliance, or other conditions that make them unsuitable for participating in this trial; A history of other malignant tumors within 5 years, except for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early-stage prostate cancer, and carcinoma in situ of the cervix.",{"count":146,"type":22},39,[111],"This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of Sacituzumab Tirumotecan and Toripalimab in the first-line treatment of recurrent\u002Fmetastatic head and neck squamous cell carcinoma patients with trop2 and CPS positive. The participants would receive Sacituzumab Tirumotecan and Toripalimab until termination criteria are met.",[150],"Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",{"date":152,"type":40},"2026-06-18",{"date":154,"type":40},"2025-07-29",{"date":156,"type":22},"2028-08-01",{"name":46,"class":47},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":173,"locationsCount":75},"100599886","phase-2-iparomlimab-and-tuvonralimab-in-hnscc-100599886","NCT07090317","Iparomlimab and Tuvonralimab in HNSCC","Iparomlimab and Tuvonralimab in Patients With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma Failed Second-line Treatment:A Prospective, Single Arm, Phase II Trial","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender; Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (with primary tumor sites in the oropharynx, oral cavity, hypopharynx, and larynx), with clinical or radiological progression after receiving 2 or more lines of anti-tumor systemic therapy in the recurrent or metastatic stage; ECOG performance status of 0 or 1; Expected survival period ≥ 12 weeks; At least one measurable lesion according to RECIST 1.1 criteria. Lesions that have undergone previous radiotherapy can be used as measurable lesions if disease progression occurs; Availability of tumor tissue for PD-L1 detection (paraffin-embedded specimens within 2 years or fresh tumor tissue); For patients with oropharyngeal cancer, the P16 detection status, determined by IHC method;\n\nNormal function of major organs within 2 weeks before treatment, meeting the following criteria:\n\nBone marrow function: Hemoglobin ≥ 100g\u002FL, white blood cell count ≥ 4.0×10\\^9\u002FL or neutrophil count ≥ 2.0×10\\^9\u002FL, and platelet count ≥ 100×10\\^9\u002FL without blood transfusion or colony-stimulating factor support; Liver function: Serum total bilirubin level ≤ 1.5 times the upper limit of normal, aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 times the upper limit of normal; Renal function: Serum creatinine level \\\u003C 1.5 times the upper limit of normal or creatinine clearance rate ≥ 60ml\u002Fmin, and blood urea nitrogen ≤ 200mg\u002FL; Urinary protein \\\u003C +; if urinary protein is +, the 24-hour total protein must be \\\u003C 500mg; Blood glucose: Within the normal range and\u002For for diabetic patients, blood glucose is controlled in a stable state during treatment; Cardiac function: No myocardial infarction within 1 year; no unstable angina; no symptomatic severe arrhythmia; no cardiac insufficiency; For women of childbearing age, the serum pregnancy test result must be negative within 7 days before the first administration of the trial drug; males with reproductive capacity or females with the possibility of pregnancy must use highly effective contraceptive methods (such as oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides) throughout the trial, and continue contraception for 12 months after the end of treatment.\n\nSubjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up; Patients whom doctors believe can benefit from the treatment.\n\nExclusion Criteria:\n\n* Tumors outside the oropharynx, larynx, hypopharynx, or oral cavity; Previous treatment with anti-CTLA-4 drugs; Central nervous system metastasis and\u002For carcinomatous meningitis; Patients with hearing loss ≥ grade 2 or neuropathy ≥ grade 2 who are currently receiving anti-tumor treatment; Patients who participated in or are participating in other drug\u002Ftherapy clinical trials within 4 weeks before the first administration of the study drug; Patients who received hematopoietic stimulating factors (such as granulocyte colony-stimulating factor (G-CSF), erythropoietin, etc.) within 1 week before the first administration of the study drug; Positive results of HIV antibody or Treponema pallidum antibody tests;\n\nPatients with active hepatitis B or hepatitis C:\n\nIf HBsAg or HBcAb is positive, additional HBV DNA testing is required (with the test result higher than the upper limit of the normal range); If HCV antibody test result is positive, additional HCV RNA testing is required (with the test result higher than the upper limit of the normal range); Active lung diseases (interstitial pneumonia, pneumonia, obstructive pulmonary disease, asthma) or a history of active pulmonary tuberculosis;\n\nHaving any uncontrollable clinical problems, including but not limited to:\n\nPersistent or active (severe) infections; Poorly controlled diabetes; Cardiac diseases (New York Heart Association class III\u002FIV congestive heart failure or heart block); The following conditions occurring within 6 months before the first administration: deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina pectoris; percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, cerebral embolism; Large amounts of pleural effusion or ascites with clinical symptoms requiring symptomatic treatment; Patients who concurrently used cytochrome P450 3A4 (CYP3A4) inhibitors within one week before screening; A history of stem cell transplantation or organ transplantation; Patients with a history of psychoactive substance abuse who are unable to abstain or a history of mental disorders; Other severe, acute or chronic medical diseases or laboratory test abnormalities that the researcher judges may increase the risks related to study participation or interfere with the interpretation of study results; Patients judged by the researcher to have poor compliance, or other conditions that make them unsuitable for participating in this trial; A history of other malignant tumors within 5 years, except for cured basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, early-stage prostate cancer, and carcinoma in situ of the cervix.",{"count":166,"type":22},30,[111],"This study is a single center, non-randomized, prospective phase II clinical trial to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab in patients with with recurrent\u002Fmetastatic head and neck squamous cell carcinoma failed second-line treatment. The participants would receive cetuximab combined with Iparomlimab and Tuvonralimab until termination criteria are met.",[150],{"date":152,"type":40},{"date":154,"type":40},{"date":156,"type":22},{"name":46,"class":47},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":75},"100642147","hidden-hearing-loss-in-older-adults-100642147","NCT07646119","Hidden Hearing Loss in Older Adults","Hidden Hearing Loss in Older Adults: Mechanisms of Speech-in-noise Perception Deficits and Associated Central Compensation","Inclusion Criteria:\n\n1. Aged 60 years or older;\n2. Bilateral pure-tone average hearing thresholds across 0.5, 1, 2, and 4 kHz ≤ 25 dB HL;\n3. Self-reported hearing difficulties identified during previous hearing screening;\n4. Fluent in Mandarin Chinese;\n5. No history of otologic disease, ear trauma, ototoxic medication history, or long-term noise exposure;\n6. No known neurological or psychiatric disorders, or other major medical conditions that may affect nervous system function.\n\nExclusion Criteria:\n\n1. Unable to comply with or complete the study assessments;\n2. Mini-Mental State Examination (MMSE) score \\\u003C 24 during previous health screening;\n3. Refuse to participate in the study","60 Years",{"count":183,"type":22},200,"The goal of this observational study is to investigate whether speech-in-noise perception deficits in older adults aged 60 years or older with objectively normal hearing thresholds are due to impaired ability of processing temporal cues in speech signals. The study further aims to examine whether cognitive and cortical mechanisms provide compensatory support for speech perception in challenging listening environments.",[186],"Hidden Hearing Loss",[188,189],"Cochlear Synaptopathy","Age-related Hearing Loss","2026-06-09",{"date":192,"type":40},"2026-06-12",{"date":194,"type":22},"2026-06-15",{"date":196,"type":22},"2027-05-30",{"name":46,"class":47},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":75},"100643373","phase-2-becotatug-vedotin-combined-with-pucotenlimab-for-locally-recurrent-resectable-head-and-neck-squamous-cell-carcinoma-100643373","NCT07632339","Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma","A Prospective, Randomized Controlled, Phase II Clinical Study of Becotatug Vedotin Combined With Pucotenlimab for Neoadjuvant and Adjuvant Treatment of Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma","BLOOM-ON","Inclusion Criteria:\n\n* Age between 18 and 75 years, inclusive, regardless of sex; Histologically or cytologically confirmed locally recurrent head and neck squamous cell carcinoma (HNSCC) that is amenable to curative surgical resection. Patients must not have received any prior systemic antineoplastic therapy for the recurrent disease. (Note: Prior systemic therapy as part of a multimodality treatment for locally advanced disease is permitted, provided that ≥6 months have elapsed from the completion of such therapy to the signing of the informed consent form); Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Estimated life expectancy ≥12 weeks; At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Previously irradiated lesions may be considered measurable if disease progression has been documented at the site; Availability of tumor tissue for PD-L1 testing (paraffin-embedded specimens collected within 2 years or fresh tumor tissue);\n\nAdequate organ function, defined as follows (assessed within 14 days prior to the first dose of the investigational product):\n\nBone Marrow: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelets (PLT) ≥100×10⁹\u002FL, hemoglobin (HB) ≥9 g\u002FdL (no blood transfusions or blood component therapy within 14 days prior to screening); Liver \\& Kidney: Serum total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (if hepatic metastasis is present, AST and ALT ≤5 × ULN are allowed). Serum creatinine ≤1.5 × ULN and calculated creatinine clearance ≥50 mL\u002Fmin (using the Cockcroft-Gault formula); Coagulation: International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5 × ULN (applies only to patients not receiving anticoagulant therapy; patients on anticoagulants must be within the therapeutic range); Thyroid Function: Thyroid-stimulating hormone (TSH) ≤1 × ULN (if TSH is abnormal, free triiodothyronine \\[FT3\\] and free thyroxine \\[FT4\\] levels must be evaluated; enrollment is permitted if FT3 and FT4 are within normal limits); Urinary Protein: Urine dipstick protein ≤1+. If urine dipstick protein is \\>1+, a 24-hour urine collection is required, and the total protein must be ≤1 g\u002Fday; Cardiac Function: Normal cardiac function, defined as a normal electrocardiogram (ECG) or ECG abnormalities with no clinical significance, and left ventricular ejection fraction (LVEF) \\>50% as determined by echocardiography.\n\nWomen of childbearing potential must have a negative serum pregnancy test prior to the first dose of the investigational product; Sexually active men and women of childbearing potential must use highly effective contraception (e.g., oral contraceptives, intrauterine devices, sexual abstinence, or barrier methods combined with spermicides) throughout the entire study period and for 90 days after the end of treatment; The patient voluntarily agrees to participate in the study, signs the informed consent form, demonstrates good compliance, and agrees to cooperate with follow-up visits.\n\nExclusion Criteria:\n\n* Presence of distant metastases or local lesions without surgical indications (Stage IVb or IVc); Disease progression occurring within 6 months following systemic therapy for locally advanced HNSCC; Re-irradiation to the head and neck region (including cervical, supraclavicular, and infraclavicular lymph nodes) within 6 months prior to enrollment; Prior treatment with PD-1\u002FPD-L1\u002FPD-L2\u002FCTLA-4 antibodies, or agents targeting activating or inhibitory receptors on T cells (e.g., OX40, CD137); Prior treatment with antibody-drug conjugates (ADCs) bearing an MMAE payload; Participation in any other drug\u002Ftreatment clinical trial within 4 weeks prior to the first dose of the investigational product, or currently participating in another trial; major surgery, unresolving adverse effects from prior surgery, live vaccines, or immunotherapy within 4 weeks prior to the first dose; radiotherapy within 2 weeks prior to the first dose; concurrent receipt of any other antineoplastic therapy; Any active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: Vitiligo not requiring systemic therapy is permitted; childhood asthma that has completely resolved and requires no intervention in adulthood is permitted. Asthma requiring medical intervention with bronchodilators is not permitted; Current use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (at doses \\>10 mg\u002Fday prednisone equivalent or equivalent efficacy) that are still being used within 2 weeks prior to enrollment; History of other malignancies within the past 5 years, except for adequately treated basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, early-stage prostate cancer, and carcinoma in situ of the cervix; Active pulmonary diseases (interstitial pneumonitis, pneumonia, obstructive pulmonary disease, asthma) or a history of active pulmonary tuberculosis;\n\nAny uncontrolled clinical conditions, including but not limited to:\n\nPersistent or active (severe) infections; Poorly controlled hypertension (persistent blood pressure \\>150\u002F90 mmHg); Poorly controlled diabetes mellitus; Cardiac diseases (New York Heart Association \\[NYHA\\] Class III\u002FIV congestive heart failure or cardiac conduction blocks); Occurrence of any of the following within 6 months prior to the first dose: deep vein thrombosis (DVT) or pulmonary embolism (PE); myocardial infarction; severe or unstable arrhythmias or angina; percutaneous coronary intervention (PCI), acute coronary syndrome (ACS), or coronary artery bypass grafting (CABG); cerebrovascular accident (CVA), transient ischemic attack (TIA), or cerebral embolism; History of psychoactive substance abuse that cannot be discontinued, or a history of psychiatric disorders; Any other severe, acute, or chronic medical condition, or laboratory abnormalities that, in the investigator's judgment, may increase the risks associated with study participation or interfere with the interpretation of study results; Poor compliance, or any other circumstances that, in the investigator's judgment, render the patient unsuitable for participation in this trial.",{"count":207,"type":22},102,[111],"This is a multicenter, randomized, controlled, Phase II clinical study designed to evaluate the efficacy and safety of neoadjuvant and adjuvant therapy with vebikotamab combined with Pucotenlimab compared to standard treatment in patients with locally recurrent resectable head and neck squamous cell carcinoma (HNSCC).\n\nInvestigational Arm:\n\nThe dosing regimen for the investigational arm is as follows:\n\nPucotenlimab: 200 mg per dose, administered intravenously (IV) every 3 weeks (Q3W). No dose adjustments are permitted; however, dosing delays are allowed up to a maximum of 12 weeks from the date of the previous dose. This is administered for two preoperative cycles.\n\nBecotatug Vedotin: 2.3 mg\u002Fkg, administered IV Q3W for two preoperative cycles.\n\nFollowing neoadjuvant therapy, patients will undergo surgery at 4 weeks ± 7 days. Postoperatively (at 6 weeks ± 3 weeks), patients will be stratified for adjuvant therapy based on pathological response:\n\nPatients who achieve a major pathological response (MPR) and have no high-risk factors will receive 6 cycles of single-agent adjuvant Pucotenlimab (200 mg\u002Fdose, Q3W).\n\nPatients who do not achieve MPR or who present with high-risk factors will receive standard postoperative adjuvant therapy.\n\nControl Arm:\n\nPatients in the control arm will undergo upfront surgery followed by standard adjuvant therapy.",[114],"2026-06-03",{"date":213,"type":40},"2026-06-08",{"date":215,"type":22},"2026-06-16",{"date":217,"type":22},"2029-06-16",{"name":46,"class":47},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":227,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":228,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":75},"100639524","hearing-and-brain-development-cohort-in-children-and-adolescents-100639524","NCT07625462","Hearing and Brain Development Cohort in Children and Adolescents","A Longitudinal Cohort Study of Hearing and Brain Development in Children and Adolescents With Hearing Loss Across Different Hearing Management Pathways and in Normal-Hearing Controls","HBD-Cohort","Inclusion Criteria:\n\n* Age no more than 18 years.\n* For the HA\u002FCI\u002FABI\u002FGT\u002FFU groups: behavioral or pure-tone hearing threshold \\>=20 dB HL, or air-conduction ABR \\>=35 dB nHL; For the normal-hearing control group: participants diagnosed as normal hearing by experienced physicians.\n\nExclusion Criteria:\n\n* Inability to cooperate with study testing procedures.",true,{"count":229,"type":22},5000,"This bidirectional observational cohort study aims to establish a Hearing and Brain Development (HBD) cohort in children and adolescents with hearing loss across different hearing management pathways, including hearing aid fitting, cochlear implantation, auditory brainstem implantation, gene therapy, and follow-up without intervention, as well as in a normal-hearing control group. Participants will undergo longitudinal assessments of hearing, speech, language, neurodevelopment, and multimodal brain function.",[232],"Hearing Loss",{"date":234,"type":40},"2026-06-04",{"date":236,"type":22},"2026-05-20",{"date":238,"type":22},"2030-12-31",{"name":46,"class":47},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":75},"100584942","accuracy-of-immediate-implant-placement-using-robotic-system-versus-dynamic-navigation-system-in-anterior-maxillae-a-random-controlled-clinical-trial-100584942","NCT06895915","Accuracy of Immediate Implant Placement Using Robotic System Versus Dynamic Navigation System in Anterior Maxillae: A Random Controlled Clinical Trial","Inclusion Criteria:\n\n* a. ≥18 years old and in good health; b. One or more maxillary incisors that cannot be retained due to non-periodontitis; c. The buccal bone plate is intact; d. No acute infection; e. The extraction socket have at least 3-5 mm apical bone.\n\nExclusion Criteria:\n\n* a. General contraindications of oral implant surgery (such as immunodeficiency, long-term use of corticosteroids); b. Treatments or diseases that may affect bone tissue metabolism (for example, taking bisphosphonates or receiving local radiotherapy); c. Periodontitis history or uncontrolled periodontitis. Bleeding of probing (BOP) positive site ≥ 10%, or probing depth (PD) ≥ 4mm; d. Heavy smokers or previous heavy smoking history (quit smoking time \\\u003C5 years or\\> 20 cigarettes per day); e. Refuse to participate in this trial.",{"count":247,"type":22},24,[25],"Prosthetic-driven immediate implant placement for optimal aesthetic restoration has been increasing in demand during the last decades but requires higher accuracy. Dynamic navigation has been reported better implant positioning in immediate implant placement compared to free hand procedure. On the basis of dynamic navigation, robotic system uses the robotic arm to replace the manual process of implant bed preparation and implant placement, therefore improving the accuracy of implant placement theoretically. The goal of this randomized controlled trial is to compare the positional implant accuracy, the surgical time, and patient satisfaction between dynamic navigation and robotic assisted immediate implant placement in maxillae. Subjects will be randomized to either group based on the allocation. The accuracy of placement will be assessed evaluating the difference between the planned and the actual position using a follow-up CBCT scan taken at the end of the surgery. Subjects will be followed up for one year to assess both patient reported and professional outcomes.",[251],"Tooth Diseases",[253,254,255],"immediate implant placement","dynamic navigation","robotic surgery","2026-05-19",{"date":258,"type":40},"2026-05-22",{"date":260,"type":22},"2026-06-01",{"date":262,"type":22},"2027-09-01",{"name":46,"class":47},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100641015","phase-2-adc-and-sbrt-for-recurrentmetastatic-salivary-gland-carcinoma-100641015","NCT07579598","ADC and SBRT for Recurrent\u002FMetastatic Salivary Gland Carcinoma","Antibody-Drug Conjugate Plus Stereotactic Body Radiotherapy in Recurrent or Metastatic Salivary Gland Carcinoma - A Phase II Exploratory Study","Inclusion Criteria:\n\n1. Provide written informed consent prior to the initiation of any study-specific procedures.\n2. Male or female patients aged 18-80 years.\n3. Histologically or cytologically confirmed head and neck squamous cell carcinoma or adenoid cystic carcinoma, expressing ADC-related targets (e.g., EGFR, TROP2), with evidence of recurrence and\u002For metastasis.\n4. Patients must have experienced disease progression after first-line standard therapy or be deemed unsuitable for such therapy, and meet the following conditions: (1) For adenoid cystic carcinoma, first-line treatment should include anti-angiogenic agents (e.g., TKIs or monoclonal antibodies), chemotherapy, or patients are considered unsuitable for standard first-line therapy by the investigator (e.g., high bleeding risk, non-healing wounds); (2) For other salivary gland carcinomas, patients must have progressed after first-line standard therapy or be unsuitable for such therapy.\n5. At least one measurable lesion according to RECIST version 1.1 based on imaging.\n6. Life expectancy of at least 6 months.\n7. ECOG performance status (PS) score of 0-1.\n8. Adequate organ function, defined by the following laboratory criteria: (1) Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL without use of granulocyte colony-stimulating factor within 14 days prior to testing; (2) Platelet count ≥ 90 × 10⁹\u002FL without transfusion within 14 days prior to testing; (3) Hemoglobin \\> 9 g\u002FdL without transfusion or erythropoietin use within 14 days prior to testing; (4) Total bilirubin ≤ 1.5 × upper limit of normal (ULN); (5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; (6) Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula); (7) Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; (8) Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. Patients with abnormal baseline TSH may still be eligible if total T3 (or FT3) and FT4 are within normal limits; (9) Myocardial enzyme levels within the normal range (isolated laboratory abnormalities deemed clinically insignificant by the investigator are acceptable); (10) Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days prior to the first dose (Cycle 1 Day 1). If a urine test result is inconclusive, a serum test is required. Women of non-childbearing potential are defined as those who are postmenopausal for at least 1 year, or who have undergone surgical sterilization or hysterectomy; (11) Willingness and ability to comply with study procedures, including treatment, contraceptive measures, scheduled visits, and follow-up assessments.\n\nExclusion Criteria:\n\n1. Diagnosis of malignancies other than head and neck tumors within 5 years prior to the first dose (except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For carcinoma in situ following curative resection).\n2. Participation in another interventional clinical study or receipt of investigational drugs\u002Fdevices within 4 weeks prior to the first dose.\n3. Prior treatment with ADC agents.\n4. Treatment of traditional Chinese medicines with antitumor indications or immunomodulatory agents (e.g., thymosin, interferon, interleukins; except for local use for pleural effusion control) within 2 weeks prior to the first dose.\n5. Known hypersensitivity to the active ingredients or excipients of the study drug.\n6. Failure to recover from toxicities and\u002For complications caused by prior interventions to ≤ Grade 1 or baseline (excluding fatigue or alopecia) prior to treatment initiation.\n7. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV-1\u002F2 antibody positive).\n8. Untreated active hepatitis B infection (defined as HBsAg positive with HBV-DNA levels above the upper limit of normal for the study center laboratory). Note: Patients with hepatitis B may still be eligible if: (1) HBV viral load \\\u003C 2.5 × 10³ copies\u002FmL (500 IU\u002FmL) prior to first dosing, and patients receive anti-HBV therapy throughout the study; (2) Patients with anti-HBc (+), HBsAg (-), anti-HBs (-), and negative HBV viral load do not require prophylactic anti-HBV therapy but must be closely monitored for viral reactivation.\n9. Active hepatitis C infection (HCV antibody positive with HCV-RNA above the lower limit of detection).\n10. Pregnant or breastfeeding women.\n11. Presence of any severe or uncontrolled systemic disease, including but not limited to: (1) Significant and symptomatic abnormalities in cardiac rhythm, conduction, or morphology on resting ECG that are difficult to control, such as complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmias, or atrial fibrillation; (2) Unstable angina, congestive heart failure, or chronic heart failure with New York Heart Association (NYHA) class ≥ II; (3) Any arterial thrombosis, embolism, or ischemic event within 6 months prior to enrollment (e.g., myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack); (4) Major surgery (e.g., craniotomy, thoracotomy, laparotomy) within 4 weeks prior to the first dose, or presence of unhealed wounds, ulcers, or fractures. Tissue biopsy or minor surgical procedures within 7 days prior to first dosing are also exclusionary, except for venous catheter placement for infusion; (5) Poorly controlled hypertension (systolic \\>140 mmHg and\u002For diastolic \\>90 mmHg); (6) Active pulmonary tuberculosis; (7) Active or uncontrolled infections requiring systemic therapy; (8) Clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction; (9) Liver diseases such as cirrhosis, decompensated liver disease, or acute\u002Fchronic active hepatitis; (10) Poorly controlled diabetes mellitus (fasting blood glucose \\>10 mmol\u002FL); (11) Proteinuria ≥ ++ on urinalysis confirmed by 24-hour urinary protein \\>1.0 g; (12) Psychiatric disorders that interfere with treatment compliance; (13) Any medical history, disease condition, treatment, or laboratory abnormality that may interfere with study results or the patient's full participation, or any other condition deemed unsuitable for enrollment by the investigator.",{"count":108,"type":22},[111],"This is a single-arm, single-center, exploratory clinical study. The study plans to enroll patients with recurrent or metastatic head and neck salivary gland carcinoma (HN-SGC) . The trial comprises two cohorts: Cohort 1 (adenoid cystic carcinoma, ACC) and Cohort 2 (non-ACC SGC). Patients in Cohort 1 will initially receive MRG003, an EGFR-targeted antibody-drug conjugate (ADC). Patients in Cohort 2 will initially receive either MRG003 (EGFR-ADC) or a TROP2-targeted ADC. The selection between these two ADC therapies for Cohort 2 will be determined by the investigator based on the expression levels of specific tumor surface receptors.\n\nTumor response will be assessed by imaging every 6 weeks (±7 days). Subjects who are assessed as having stable disease (SD) on two consecutive evaluations or who develop oligometastatic progression will receive stereotactic body radiation therapy (SBRT). Following SBRT, maintenance therapy with the original ADC will be continued.\n\nTreatment discontinuation will be permitted due to disease progression, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or other protocol-specified reasons, whichever occurs first. After treatment completion, all subjects will enter a post-treatment phase for safety visits and survival follow-up. For subjects who discontinue treatment for reasons other than disease progression or death, tumor progression follow-up will also be conducted during the post-treatment period.",[275,276,277],"Adenoid Cystic Carcinoma of the Head and Neck","SBRT","Antibody-drug Conjugates","2026-05-05",{"date":280,"type":40},"2026-05-12",{"date":282,"type":22},"2026-05-01",{"date":284,"type":22},"2027-12-12",{"name":46,"class":47},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100640735","personalized-two-stage-regional-citrate-anticoagulation-for-crrt-in-patients-with-citrate-metabolism-impairment-100640735","NCT07579663","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study","PRECISE","Inclusion Criteria:\n\nA. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and\u002For microcirculation disorder (mean arterial pressure \\\u003C65 mmHg requiring vasopressor therapy and lactate ≥2 mmol\u002FL); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate \\>150 ml\u002Fmin); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.\n\nExclusion Criteria:\n\nA. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.",{"count":295,"type":22},142,[25],"The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.",[299,300,301],"AKI - Acute Kidney Injury","CKD 5D, Hemodialysis","Hepatic Failure",[303,304],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)",{"date":280,"type":40},{"date":278,"type":22},{"date":308,"type":22},"2028-08-14",{"name":46,"class":47},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":328,"locationsCount":329},"100638883","surgical-robot-or-static-guide-for-dental-implant-placement-100638883","NCT07577245","Surgical Robot or Static Guide for Dental Implant Placement","Comparison of Robotic and Static Guide Assisted Surgery for Rehabilitation of Monolateral Distal Extension Edentulism With Implant-supported Fixed Partial Dentures: a Multicenter Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Monlateral distal free-end edentulism\n3. Presence of natural teeth or reliable fixed restorations mesial to the edentulous area to provide support and stability for the surgical guide\n4. Preoperative CBCT assessment shows available bone height ≥8 mm and bone width ≥5 mm in the edentulous area, allowing implant placement without concomitant complex bone augmentation\n\nExclusion Criteria:\n\n1. Uncontrolled periodontitis or acute oral infection\n2. Uncontrolled systemic diseases (e.g., diabetes, severe osteoporosis) or pregnancy\u002Flactation\n3. History of head and neck radiotherapy or current use of intravenous bisphosphonates\n4. Severe limited mouth opening (interincisal distance \\\u003C35 mm) affecting surgical instrument manipulation\n5. Psychiatric or psychological disorders that prevent cooperation with study procedures",{"count":318,"type":22},112,[25],"Precision in implant placement is a key requirement for safety and to support the long-term success of dental implants. Optimal placement requires implementing a diagnostic standard that includes careful digital planning based on CBCT and intraoral scanning data. Once the case is planned, adherence to the plan during surgery cannot be achieved through freehand surgery; guidance is needed. Guidance has two key components: real-time tracking of osteotomy site preparation (achieved with dynamic navigation technology) and constraining instrumentation to the planned site (achieved through the application of a surgical template that guides the position and direction of bone drilling). Robotic surgery enables both objectives: real-time monitoring and guidance. Previous studies have shown high precision for both static guidance and robotic surgery, but the evidence is limited to a few small-sample-size studies, mostly in single-tooth gap applications. Evidence of the applicability of the technologies to more challenging clinical conditions, such as the more complex distal extension, is lacking. In addition, so far, dental implant robotics studies have focused only on metrics of implant placement precision and have failed to capture a broader context that may be equally important for clinical decision-making and patient preferences. In this respect, it is important to emphasize the recent implant dentistry core outcome set and measurement (ID-COSM) framework that mandates capturing and reporting a full range of outcomes across multiple domains.",[322],"Partial Edentulism Class II",{"date":324,"type":40},"2026-05-11",{"date":260,"type":22},{"date":327,"type":22},"2028-10-30",{"name":46,"class":47},2,{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":48},"100346533","stents-post-dilation-with-dcb-or-poba-in-femoropopliteal-arteries-100346533","NCT03791970","Stents Post-dilation With DCB or POBA in Femoropopliteal Arteries","A Prospective, Single Center, Case-cohort Study Using the Orchid Drug Coated Balloon for Post-Dilatation of the Stent for Treatment of Long Lesions in Femoropopliteal Arteries","SFPA","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. The subject is legally competent and able to understand the information on the study, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF);\n3. Rutherford Category 2-4;\n4. Target de novo lesion(s) or non-stented restenotic lesion(s) has angiographic evidence of long-term occlusion (by visual estimate ≥10cm) and is amenable to treatment with stents placement;\n5. Patients must be able to be treated with DCB or POBA for post-dilation;\n6. Target vessel reference diameter is 4.0-7.0 mm (by visual estimate) and able to be treated with available device size matrix;\n7. At least one patent native outflow artery to the ankle free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT permitted; treatment of in-flow disease is permitted prior to treatment with stents placement).\n8. No other prior vascular interventions (including contralateral limb) within 2 weeks before and\u002For planned 30 days after the protocol treatment, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;\n9. Female subjects of childbearing potential have a negative urine or serum pregnancy test within 7 days prior to index procedure;\n10. Lesion location starts ≥1 cm below the common femoral bifurcation and P1 popliteal artery.\n\nExclusion Criteria:\n\n1. Pregnant, lactating, or planning on becoming pregnant or men intending to father children;\n2. Contraindication to stent or DCB or POBA per current information for use (IFU);\n3. Life expectancy of \\\u003C1 year;\n4. Inability to take required antiplatelet\u002Fanticoagulant medications, or known contraindication (including allergic reaction) or sensitivity to contrast media, nickel, titanium or tantalum that cannot be adequately managed with pre- and post-procedure medication;\n5. Intended treatment of outflow disease during the index procedure;\n6. Intended use of laser, atherectomy or cryoplasty during index procedure;\n7. Sudden symptom onset, acute vessel occlusion, or acute or subacute thrombus in target vessel;\n8. History of stroke within 3 months;\n9. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment;\n10. Participation in an investigational drug or another investigational device study until this study's primary endpoint is reached or previous enrollment in this study;\n11. Another medical condition, which, in the opinion of the Investigator, may cause the patient to be noncompliant with the Concern\u002FInformation Need\u002FParticipation Willingness (CIP) or confound data interpretation;\n12. Target vessel and\u002For lesion involves a previously placed stent.",{"count":339,"type":22},180,[25],"To compare the efficacy and safety of stent angioplasty with Orchid 035 Drug Coated Dilatation (DCB) and Plain Old Balloon Angioplasty (POBA) for post-dilatation for long (\\>10cm) femoropopliteal chronic total occlusion.",[343],"Peripheral Artery Disease","2026-04-29",{"date":282,"type":40},{"date":347,"type":40},"2019-01-01",{"date":349,"type":22},"2026-12-31",{"name":46,"class":47},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":4},"100634121","phase-2-postoperative-radiotherapy-with-nimotuzumab--benmelstobart-in-intermediate-risk-head-and-neck-squamous-cell-carcinoma-100634121","NCT07535567","Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma","Postoperative Radiotherapy And Nimotuzumab With or Without Benmelstobart Adjuvant Therapy in Patients With Head and Neck Squamous Cell Carcinoma Having Intermediate-Risk Pathological Factors: A Multicenter Prospective Randomized Controlled Study","NimoBenSeq","Inclusion Criteria:\n\n* Age ≥ 18 years\n* ECOG performance status: 0-2\n* Histologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx); oropharyngeal cancer must be p16-negative (p16 positivity defined as ≥70% staining)\n* Completionof curative-intent surgery, with any of the following intermediate-risk factors present postoperatively:\n\n  ①pT3-4a;\n\n  ②N2 disease (excluding cases with extranodal extension);\n\n  ③Closemargin \\\u003C 5 mm;\n\n  ④Lymphovascular and\u002For perineural invasion;\n\n  ⑤Invasion depth \\> 5mm for T2 oral cavity cancer\n* Laboratory tests must meet the following criteria:\n\n  ①Hematologic parameters (within 14 days without transfusion or blood products): a. Hemoglobin (Hb) ≥80 g\u002FL; b.Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL; c. Platelet count (PLT) ≥ 80 × 10⁹\u002FL;\n\n  ②Biochemical parameters: a. Bilirubin (BIL) \\\u003C 1.5 × upperlimit of normal (ULN); b.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;\n* Expected survival time ≥ 6 months;\n* Women of child bearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use reliable contraception during the study period; Male subjects must use reliable contraception from before treatment initiation until 120 days after the last dose of study drug\n* With PD-L1 immunohistochemistry testing\n* Participant voluntarily agrees to participate in this study and signs the informed consent form\n\nExclusion Criteria:\n\n* Pregnancy or lactation, or intention to become pregnant during the study period.\n* Presence of active autoimmune disease or immunodeficiency, including but not limited to: myasthenia gravis, interstitial pneumonia, enteritis, autoimmune hepatitis, hypophysitis, vasculitis, nephritis, or hyperthyroidism.\n* Known human immunodeficiency virus (HIV) infection, history of autoimmune diseases, or history of organ transplantation.\n* Use of systemic immunosuppressive drugs within 2 weeks prior to initiation of study treatment, or anticipated need for systemic immunosuppressive therapy during the study treatment period.\n* Diagnosis of another malignancy within 3 years prior to enrollment.\n* History of Grade I or higher myocardial ischemia or myocardial infarction, severe arrhythmia, or ≥ Grade 2 congestive heart failure (New York Heart Association \\[NYHA\\] classification) within 6 months prior to enrollment.\n* Participation in another clinical trial or completion of another clinical trial within 4 weeks prior to enrollment.\n* Prior treatment of immunotherapy (including PD-1\u002FPD-L1\u002FCTLA-4 antibodies) or anti-EGFR agents.\n* Known or suspected allergy to the investigational product or any drug related to this trial.\n* Any other severe medical condition that, in the investigator's judgment, may compromise patient safety or interfere with the subject's ability to complete the study.",{"count":360,"type":22},386,[111,362],"PHASE3","A multicenter, randomized, controlled, open-label, Phase II\u002FIII clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative head and neck squamouscell cancer patients with intermediate-risk pathological factor. The primary endpoint is the 3-year disease-freesurvival (DFS). A total of 193 patients will be enrolled in both the experimental and control groups, resulting in a total planned enrollment of 386 patients.",[365],"Head and Neck Squamous Cell Carcinoma",[367],"intermediate-risk pathological risk factor","2026-04-24",{"date":370,"type":40},"2026-04-30",{"date":278,"type":22},{"date":373,"type":22},"2028-12-31",{"name":46,"class":47},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":227,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":384,"studyType":85,"phases":4,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":48},"100624225","diagnostic-accuracy-of-oral-images-opgs-biomarkers-and-questionnaires-vs-clinical-assessment-for-periodontal-disease-postnct07164573-100624225","NCT07406867","Diagnostic Accuracy of Oral Images, OPGs, Biomarkers and Questionnaires vs. Clinical Assessment for Periodontal Disease (PostNCT07164573)","Diagnostic Accuracy of Oral Images, Orthopantomographs (OPGs), Biomarkers and Self-Reported Questionnaires vs. Clinical Assessment for Detecting Periodontal Health and Disease: a Multi-center Diagnostic Study","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Seeking dental care at one of the participating study centers.\n* Ability to understand and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Edentulous patients (complete tooth loss).\n* Pregnancy or lactation.\n* History of periodontal therapy (other than supragingival prophylaxis\u002Fcleaning) within the past 12 months.\n* Use of antibiotic medication within the 3 months prior to enrollment.",{"count":383,"type":22},2000,"1 Day","This multi-center, cross-sectional diagnostic trial evaluates the accuracy of multiple non-invasive screening tools-including self-reported questionnaires, intra-oral photographs, orthopantomographs (OPGs), intraoral scans (IOS), and salivary\u002Fmicrobial biomarkers-for detecting periodontal health and diseases (gingivitis and periodontitis Stages I-IV), using full-mouth clinical periodontal examination as the reference standard. A total of 2,000 participants will be recruited across five international centers. Diagnostic performance (sensitivity, specificity, AUROC) of individual and combined methods will be assessed using logistic regression and machine learning algorithms to establish an optimized multi-modal screening algorithm.",[387,388,389],"Periodontal Disease","Gingivitis","Periodontitis",[391,392,393,394,395,396],"Diagnosis","ArtiLcial Intelligence","Periodontal Diseases","Radiography","Machine Learning","Photography",{"date":370,"type":40},{"date":399,"type":40},"2026-03-01",{"date":401,"type":22},"2029-03-01",{"name":46,"class":47},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":75},"100635181","is-professional-tooth-cleaning-necessary-for-managing-gingivitis-gingival-inflammation-if-subjects-use-intelligent-toothbrushes-100635181","NCT07549347","Is Professional Tooth Cleaning Necessary for Managing Gingivitis (Gingival Inflammation) if Subjects Use Intelligent Toothbrushes?","Optimal Oral Care Regimen With or Without Professional Mechanical Plaque Removal in Managing Gingivitis (Gingival Inflammation): A Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. ≧18 years old and \\\u003C 65 years old\n2. Gingivitis, Stage I and Localized Stage II Periodontitis\n3. With more than 20 teeth\n4. Agree to use the electronic I-brush with the Oral-B APP\n\nExclusion Criteria:\n\n1. Presence of any systemic disease that can alter the outcome of periodontal treatment\n2. Pregnancy or lactation during the study\n3. Having received antibiotics within the previous 3 months\n4. Having received professional periodontal treatment within the previous 3 months\n5. With ongoing orthodontic treatment","64 Years",{"count":412,"type":22},92,[25],"Periodontitis is highly prevalent and develops from plaque-induced gingivitis. Managing gingivitis is key to preventing periodontitis and its complications. Professional mechanical plaque removal (PMPR) with oral hygiene guidance is effective for gingivitis, but large-scale implementation-especially in China-faces challenges such as workforce shortages. Meanwhile, patient compliance with daily oral hygiene remains poor. An optimal oral care regimen featuring an intelligent electric toothbrush (i-Brush) has shown promise in enhancing self-care adherence and efficiency. However, it remains unclear whether PMPR is still necessary when used in conjunction with this optimal oral care regimen. This study aims to verify whether the i-Brush-based regimen is non-inferior to the combination of PMPR and the regimen in improving gingival inflammation in gingivitis and stage I periodontitis.",[388,389],[417,418,419,420,421],"artificial intelligence","internet of things network","oral hygiene instruction","professional mechanical plaque removal","mobile health","2026-04-17",{"date":368,"type":40},{"date":425,"type":40},"2026-03-09",{"date":427,"type":22},"2027-03-01",{"name":46,"class":47},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":227,"sex":17,"minAge":18,"maxAge":435,"enrollmentInfo":436,"targetDuration":438,"studyType":85,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":75},"100615505","discovery-and-validation-of-periodontitis-biomarkers-100615505","NCT07293481","Discovery and Validation of Periodontitis Biomarkers","Inclusion Criteria:\n\n1. Adults between 18 and 40 years of age;\n2. Diagnosed with varying degrees of periodontal disease, including gingivitis and stage I periodontitis;\n3. Voluntarily agree to participate in the study, have signed the informed consent form, and are able to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Individuals who have received antibiotic treatment within the past 3 months;\n3. Individuals who have received periodontal treatment (including supragingival scaling) within the past 6 months;\n4. Individuals with mucosal or salivary gland diseases (e.g., Sjögren's syndrome);\n5. Individuals with severe systemic diseases, immune dysfunction, or health conditions that contraindicate surgery;\n6. Individuals who are unwilling to cooperate with the study.","40 Years",{"count":437,"type":22},228,"2 Years","Periodontitis is a major public health issue in China: it is responsible for loss of masticatory function in 60 million older adults, and 400-500 million adults are on the same disease trajectory. In addition, gingivitis and early-stage periodontitis are highly prevalent in all age groups. The Lancet 2021 burden of disease study provides worrying projections for China's oral health, with a 47.8% increase in advanced-stage periodontitis and a 217% increase in edentulism by the year 2050. The numbers are not manageable by the Chinese health system unless a series of coordinated actions are implemented: i) health education promoting oral hygiene in school and the workplace; ii) effective AI-based self-detection strategies and accurate identification of high-risk subjects; iii) efficient treatment modalities; and iv) reorganization of the health system.\n\nWe have developed, patented, and validated a self-detection AI-based screening test for the general population through an app. It is based on a few validated questions and the performance of a lateral flow immunoassay to detect activated matrix metalloproteinase 8 (aMMP8). The algorithm enables accurate self-detection of severe periodontitis. The system, however, cannot identify subjects without clinically evident periodontitis (subjects who present with superficial inflammation consistent with gingivitis and incipient periodontitis) who will develop the disease, which, therefore, should be the target of early interventions. This limitation is due to insufficient knowledge of the process that turns superficial inflammation (gingivitis) into periodontitis. This limitation is apparent in the recently published NIH-sponsored American diagnostic trial results to detect periodontitis onset biomarkers (and progression). In their study, Teles et al. (2024) show that almost 24% of gingivitis subjects progress to periodontitis over a 12-month period but failed to identify salivary or serum biomarkers. Similarly, our recently completed study (Li et al. in preparation) did not identify highly accurate biomarkers for disease onset and progression. Importantly, the American and our study have tested putative biomarkers identified based on the current crude knowledge of the disease process. Gaps in fundamental knowledge are now apparent and limit our ability to detect periodontitis early. In addition, the current crude differential diagnosis based on clinical examination with a periodontal probe with millimeter markings cannot accurately differentiate gingivitis from early-stage periodontitis, complicating the ground truth definition (gold standard).\n\nIn the current study, we propose implementing a multi-omics approach to test the ability to discriminate a mixed population of clinically undifferentiable gingivitis and stage I periodontitis into two or more clusters. In this biomarker discovery phase, we plan to use multiple state-of-the-art methods: i) laser scanning microdissection proteomics of tissue biopsies, ii) conventional salivary proteomics, iii) tissue biopsy transcriptomics, and iv) shotgun microbiome analysis. The methods will be applied in an agnostic approach to test the following hypotheses:\n\n1. It is possible to identify two or more clusters of subjects from a mixed population of gingivitis and stage I periodontitis subjects.\n2. The clusters differ based on host-derived biomarkers and\u002For microbiome factors and the risk of progression to periodontitis.\n3. The biomarker pathways and microbial virulence factors among subjects identified according to the different approaches used to explore disease biology are generally consistent.\n4. It is possible to identify a limited set of biomarkers that can be used to predict periodontitis onset and thus target early interventions for this high-risk population.",[389,441,442],"Biomarker in Early Diagnosis","Saliva",{"date":444,"type":40},"2026-04-20",{"date":446,"type":40},"2025-07-21",{"date":448,"type":22},"2027-10-31",{"name":46,"class":47},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":75},"100627162","phase-3-postoperative-radiotherapy-combined-with-nimotuzumab-followed-by-benmelstobart-in-high-risk-patients-with-head-and-neck-squamous-cell-carcinoma-100627162","NCT07445048","Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma","A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial of Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma Who Are Ineligible for Cisplatin Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients ineligible for cisplatin chemotherapy, defined as meeting any of the following:① Age \\> 70 years;② Renal insufficiency (creatinine clearance \\\u003C 50 mL\u002Fmin; criterion ⑩ below does not apply if this criterion is met);③ Severe tinnitus or hearing impairment (requiring hearing aid, or audiometry showing ≥ 25 dB loss at two consecutive frequencies);④ Unable to receive intravenous hydration (e.g., due to cardiac dysfunction or other comorbidities, as judged by the investigator);⑤ Neuropathy \\> Grade 1;⑥ Patient refusal of chemotherapy.\n3. Histologically confirmed locally advanced head and neck squamous cell carcinoma (AJCC 8th edition Stage III-IVB), including oral cavity cancer, HPV-negative\u002Funrelated oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer.\n4. Underwent radical surgery with at least one high-risk feature:\n\n   Extracapsular extension (ECE) of lymph node metastasis; Close margin (\\\u003C 1 mm) or positive margin;\n   * 4 metastatic lymph nodes, or multiple perineural invasions.\n5. No evidence of distant metastasis on imaging.\n6. Sufficient tumor tissue available for EGFR and PD-L1 testing; for oropharyngeal cancer, HPV\u002Fp16 testing is required (testing may be waived if results are already available).\n7. Expected survival ≥ 6 months.\n8. ECOG performance status 0-1.\n9. Adequate hematologic function:\n\n   WBC ≥ 3 × 10⁹\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL.\n10. Adequate renal function:Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) \\> 50 mL\u002Fmin (calculated by Cockcroft-Gault formula):\n\n    Female: CrCl = (140 - Age) × Weight (kg) × 0.85 \u002F (72 × Scr (mg\u002FdL)) Male: CrCl = (140 - Age) × Weight (kg) × 1.00 \u002F (72 × Scr (mg\u002FdL))\n11. Adequate hepatic function:\n\n    Total bilirubin ≤ 1.5 × ULN; AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN.\n12. Women of childbearing potential: negative serum or urine pregnancy test within 14 days before enrollment, and agreement to use effective contraception during the study.Male subjects: use effective contraception from the start of treatment until 180 days after the last study drug administration.\n13. Voluntary participation in the study, signed written informed consent, good compliance, and willingness to comply with follow-up procedures.\n\nexclusion Criteria:\n\n1. Prior radiotherapy for head and neck cancer before enrollment.\n2. Prior treatment with similar immunological or targeted agents.\n3. Participation in another interventional clinical trial within 30 days prior to screening.\n4. Evidence of distant metastasis.\n5. History of other malignancy within the previous 5 years, except cured carcinoma in situ of the cervix, non-melanoma skin cancer, localized differentiated thyroid cancer (papillary \u002F follicular), localized prostate cancer, and ductal carcinoma in situ.\n6. Uncontrolled concurrent medical conditions (e.g., heart failure, diabetes mellitus, hypertension, thyroid disease, psychiatric disorders, etc.).\n7. Known HIV infection, active viral hepatitis, or active tuberculosis.\n8. Major surgical procedure within 30 days before the first dose of study medication, or planned major surgery during the study.\n9. Hypersensitivity to any study drug or their components.\n10. Pregnancy (confirmed by serum or urine HCG test) or lactating women; subjects of childbearing potential unwilling or unable to use effective contraception (for both male and female subjects) until at least 6 months after the last study treatment.\n11. Subjects considered inappropriate for study participation by the investigator.\n12. Subjects unwilling to participate in the study or unable to provide written informed consent.",{"count":458,"type":22},370,[362],"A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and neck squamous cell carcinoma who are ineligible for cisplatin chemotherapy.\n\nThe primary endpoint is disease-free survival (DFS). A total of 185 patients will be enrolled in both the study group and the control group, respectively, with a total planned enrollment of 370 patients. Enrollment is expected to be completed within 2 years, followed by a 3-year follow-up period after the last patient is enrolled.",[462,463,464],"Head & Neck Squamous Cell Carcinoma","Head & Neck Cancer","Postoperative Adjuvant Treatment","2026-04-14",{"date":422,"type":40},{"date":468,"type":40},"2026-03-04",{"date":470,"type":22},"2031-03-05",{"name":46,"class":47},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":479,"minAge":480,"maxAge":56,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":483,"briefSummary":484,"conditions":485,"keywords":489,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100633977","impact-of-day-2-versus-day-3-fresh-embryo-transfer-on-live-birth-rate-in-poor-prognosis-patients-100633977","NCT07533695","Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients","Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis POSEIDON Group 4 Patients: A Single-Center, Parallel-Group, Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n* 1: Meet the definition of POSEIDON Category 4: age ≥ 35 years, with antral follicle count (AFC) \\\u003C 5 or anti-Müllerian hormone (AMH) \\\u003C 1.2 ng\u002FmL\n* 2: Undergoing first or second IVF\u002FICSI cycle\n* 3: Undergoing controlled ovarian hyperstimulation (COH) using a gonadotropin-releasing hormone (GnRH) antagonist protocol, with at least 1 oocyte retrieved\n* 4: Provide written informed consent\n\nExclusion Criteria:\n\n* 1: Use of donor oocytes\u002Fsperm, or planned preimplantation genetic testing (PGT)\n* 2: Severe immune or chromosomal abnormalities\n* 3: Uterine cavity abnormalities (i.e., submucous fibroids, complete uterine septum, severe intrauterine adhesions, etc.) or untreated, ultrasound-visible hydrosalpinx\n* 4: Presence of severe underlying diseases (e.g., uncontrolled hypertension\u002Fdiabetes mellitus, active malignant tumors)\n* 5: History of recurrent implantation failure (≥2 cycles) or recurrent miscarriage (≥2 episodes)\n* 6: Progesterone level \\> 1.5 ng\u002FmL on the day of human chorionic gonadotropin (hCG) trigger","FEMALE","35 Years",{"count":482,"type":22},470,[25],"This study aimed to compare the efficacy (live birth rate) of fresh embryo transfer on Day 2 versus Day 3 in POSEIDON Group 4 patients, and to determine the optimal timing of embryo transfer for this population. It is a single-center, parallel-group, open-label prospective randomized controlled trial, and outcome assessors are masked. The main questions it aims to answer are:\n\nIs there a significant difference in the live birth rate between Day 2 and Day 3 fresh embryo transfer in patients with POSEIDON Category 4 low prognosis? What are the differences in secondary outcomes (including clinical pregnancy rate, ongoing pregnancy rate, implantation rate, embryo utilization rate, miscarriage rate, incidence of moderate\u002Fsevere OHSS, and adverse neonatal outcomes) between the two embryo transfer timings, and which timing is safer and more effective for this patient population?\n\nA total of 470 patients meeting the POSEIDON Category 4 criteria will be enrolled and randomly assigned to the Day 2 Fresh Embryo Transfer Group and the Day 3 Fresh Embryo Transfer Group in a 1:1 ratio using stratified block randomization. Researchers will compare the two groups to clarify the difference in live birth rate (primary outcome) and other secondary outcomes, so as to determine the optimal embryo transfer timing.\n\nParticipants will:\n\n* Be female patients aged ≥ 35 years with antral follicle count (AFC) \\\u003C 5 or anti-Müllerian hormone (AMH) \\\u003C 1.2 ng\u002FmL, undergoing the first or second IVF\u002FICSI cycle, receiving controlled ovarian hyperstimulation (COH) with the GnRH antagonist protocol, and having ≥ 1 oocyte retrieved (excluding those using donor oocytes\u002Fsperm, with uterine cavity abnormalities, or complicated with severe underlying diseases).\n* Be randomly assigned to either the Day 2 Fresh Embryo Transfer Group or the Day 3 Fresh Embryo Transfer Group, and receive embryo transfer according to the corresponding group's protocol\n* Receive routine luteal support treatment after embryo transfer\n* Attend follow-up visits at multiple time points (on the day of transfer, 12-15 days after transfer, 28 days after transfer, during pregnancy, and after delivery) to collect relevant clinical and laboratory data for outcome assessment.\n* Undergo safety evaluation throughout the study; the study will adopt intention-to-treat (ITT) as the main statistical method and per-protocol (PP) as the sensitivity analysis, with subgroup analysis by age, AMH level, and number of oocytes retrieved, following ethical norms and data quality control requirements.",[486,487,488],"POSEIDON Category 4","Low Prognosis in Assisted Reproductive Technology","Female Infertility Due to Diminished Ovarian Reserve",[490,491,492,493,494],"fresh embryo transfer","in-vitro fertilization","POSEIDON","low prognosis","diminished ovarian reserve","2026-04-09",{"date":497,"type":40},"2026-04-16",{"date":499,"type":22},"2026-03-30",{"date":501,"type":22},"2027-12-31",{"name":46,"class":47},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":384,"studyType":85,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":520,"leadSponsor":521,"locationsCount":4},"100631789","development-and-validation-of-the-periodontal-map-derived-from-ios-and-cbct-registration-for-diagnosis-and-treatment-planning-in-moderate-to-severe-periodontitis-100631789","NCT07505251","Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Planning in Moderate-to-severe Periodontitis","Inclusion Criteria:\n\n1. Aged ≥ 18 years.\n2. Diagnosed with Stage II-IV periodontitis according to the 2018 Classification of Periodontal Diseases.\n3. Presence of at least one tooth requiring periodontal surgery (including open flap debridement or regenerative surgery) due to periodontitis, where the intra-bony defect can be exposed intra-operatively for measurement.\n4. Voluntary participation and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Presence of uncontrolled systemic diseases that significantly affect surgery or tissue healing, such as uncontrolled diabetes mellitus or immunodeficiency.\n3. History of head and neck radiotherapy.\n4. Inability to cooperate with the required study examinations.",{"count":510,"type":22},80,"This prospective diagnostic study aims to validate the clinical utility of a \"Periodontal Panoramic Map\" generated by the PerioAI V2.0 system, an artificial intelligence-based platform that integrates intraoral scans and cone-beam CT data, for preoperative diagnosis and surgical planning in patients with moderate to severe periodontitis (Stage II-IV). Current clinical standards-manual probing and two-dimensional radiography-have inherent limitations in accurately visualizing complex three-dimensional bone defect morphology, leading to potential underestimation of disease severity and suboptimal surgical outcomes. Building upon our team's previously published high-precision PerioAI V1.0 system, this study will enroll 80 patients requiring periodontal surgery. Preoperative intraoral scans and cone-beam CT images will be acquired as part of routine care, and the PerioAI V2.0 system will automatically generate a \"Periodontal Panoramic Map\" with intelligent outputs including probing depth, clinical attachment loss, bone defect morphology classification, furcation involvement grading, and automated measurements of key parameters such as intra-bony defect depth and width. These automated diagnostic results will be compared against the gold standard of full mouth clinical examination and intra-operative direct measurements and observations obtained during periodontal surgery under strict blinded conditions. The primary outcome measures are the accuracy of bone defect morphology classification and the agreement between automated and intra-operative linear measurements assessed by intraclass correlation coefficients and Bland-Altman analysis. Secondary outcomes include accuracy of probing depth, clinical attachment loss, periodontitis staging and grading, furcation involvement grading and treatment planning. This study will provide critical evidence supporting the paradigm shift in periodontal surgery from experience-dependent assessment to data-driven precision medicine, ultimately offering clinicians an intuitive, quantitative, and three-dimensional visualization tool for optimized surgical decision-making.",[513,514,515],"Periodontitis Stage II","Periodontitis Stage III","Periodontitis Stage IV","2026-03-26",{"date":518,"type":40},"2026-04-01",{"date":518,"type":22},{"date":373,"type":22},{"name":46,"class":47},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":538,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":75},"100628835","resection-and-defect-repair-of-oral-cancer-aided-by-mixed-reality-technology-100628835","NCT07466810","Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology","Prospective Clinical Study in Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology Based on UE5 Engine","Inclusion Criteria:\n\n1. Definite pathological diagnosis of oral cancer before surgery;\n2. Defects suitable for free flap reconstruction;\n3. Patients have signed the informed consent form and are willing to cooperate with postoperative follow-up.\n\nExclusion Criteria:\n\n\\- Poor general condition, evaluated as unable to tolerate surgical treatment.\n\n-Exclusion Criteria (After Enrollment)\n\nSubjects who have been enrolled in this trial will be excluded if they meet any of the following conditions:\n\n1. Violation of important inclusion criteria;\n2. Subjects did not receive surgical treatment;\n3. No observation data after randomization. Withdrawal Criteria Withdrawal of subjects from the trial refers to cases where enrolled subjects are determined by the investigator to withdraw from the trial due to conditions that make it inappropriate to continue the trial. In accordance with the informed consent form, subjects have the right to withdraw from the trial midway. Subjects who do not explicitly propose to withdraw but stop receiving treatment and tests and are lost to follow-up are also considered \"withdrawn\" (or \"lost to follow-up\"). The reason for withdrawal should be understood and recorded as much as possible, such as: poor subjective curative effect; inability to tolerate certain adverse reactions; inability to continue participating in the clinical study due to personal reasons; economic factors; or lost to follow-up without stating the reason.\n\n(1) Aggravation or deterioration of the condition during the trial that requires emergency measures; (2) Occurrence of certain comorbidities, complications or special physiological changes in subjects during the trial, making it inappropriate to continue participating in the trial; (3) Voluntary withdrawal by the subject.\n\nData Handling of Withdrawn Subjects\n\nRegardless of the reason, the complete clinical data of subjects who withdraw from the trial shall be retained. For all withdrawn subjects, the trial conclusion form and the reason for withdrawal shall be filled in the case report form (CRF). Generally, there are 6 types of reasons: occurrence of adverse events (including adverse drug reactions and allergic reactions), lack of efficacy (deterioration of condition or occurrence of complications), violation of the trial protocol (including poor compliance), lost to follow-up (including voluntary withdrawal by the patient), termination by the sponsor, or others.",{"count":166,"type":22},[25],"The objective of this exploratory clinical trial is to apply Unreal Engine 5 (UE5)-based Mixed Reality (MR) technology to achieve real-time stereoscopic visualization of surgical planning, personalized free flap harvest and defect reconstruction, accurate oral cancer resection, and precise morphological and volumetric matching of the reconstructed free flap to the defect site.\n\nResearchers adopted a parallel controlled design, with participants randomized into three groups: Experimental Group 1 (undergoing Mixed Reality \\[MR\\] technology-assisted surgery), Experimental Group 2 (undergoing virtual surgical guide-assisted surgery), and Control Group (undergoing conventional surgery). A total of 30 participants will be recruited, with 10 cases in each group.\n\nThe primary purpose is to confirm the effectiveness of MR technology in assisting oral cancer resection, free flap design, harvest, and defect reconstruction. Allocation concealment will be implemented via the sealed envelope method.",[533,534,535,536,537],"Tongue Squamous Cell Carcinoma","Mixed Reality","Virtual Surgical Planning","Free Flap","Oral Cancer",[534,539,540,541,542,536,535,537],"tongue reconstruction","Unreal Engine 5","Glossectomy","Surgical guide","2026-03-18",{"date":545,"type":40},"2026-03-20",{"date":518,"type":22},{"date":548,"type":22},"2027-10-01",{"name":46,"class":47},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":479,"minAge":480,"maxAge":56,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":4},"100630660","the-impact-of-assisted-hatching-on-pregnancy-outcomes-after-vitrified-warmed-embryo-transfer-in-advanced-age-patients-100630660","NCT07490561","The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients","The Impact of Laser-Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1: Female age ≥ 35 years\n* 2: First or second vitrified-warmed embryo transfer cycle\n* 3: Quality of embryos for transfer meeting the criteria: Grade I, II, CP or above (cleavage-stage embryos); Grade 4BC\u002FCB or above (blastocysts)\n* 4: Provide written informed consent\n\nExclusion Criteria:\n\n* 1: Use of donor oocytes or sperm, or planned preimplantation genetic testing (PGT)\n* 2: Severe immune or chromosomal abnormalities\n* 3: Uterine cavity abnormalities (i.e., adenomyosis, submucous uterine fibroids, hydrosalpinx, uterine septum, and endometrial polyps)\n* 4: Embryos with an abnormal zona pellucida\n* 5: Complicated with severe underlying diseases (e.g., uncontrolled hypertension\u002Fdiabetes mellitus, active malignant tumors)\n* 6: A history of recurrent implantation failure (≥2 cycles) or recurrent miscarriage (≥2 episodes)",{"count":558,"type":22},916,[25],"The goal of this clinical trial is to evaluate the effect of laser assisted hatching (LAH) on pregnancy outcomes, with live birth rate as the primary outcome, in advanced age infertile women aged ≥35 years who are undergoing non-donor IVF\u002FICSI cycles and planning vitrified-warmed embryo transfer. It also aims to monitor the safety of LAH and assess various secondary pregnancy and neonatal outcomes. The main questions it aims to answer are:\n\nDoes laser assisted hatching improve the live birth rate in advanced age women undergoing vitrified-warmed embryo transfer? Does laser assisted hatching affect secondary outcomes including implantation rate, biochemical pregnancy rate, clinical pregnancy rate, ectopic pregnancy rate, ongoing pregnancy rate, miscarriage rate, multiple pregnancy rate, preterm birth rate, and rates of obstetric and neonatal complications as well as congenital anomalies? Researchers will compare the Laser Assisted Hatching (LAH) Group to the Control Group (without LAH) to see if LAH can improve pregnancy outcomes in the study population.\n\nParticipants will:\n\n* Be randomly assigned to either the LAH Group or the Control Group at a 1:1 ratio, stratified by age (\\\u003C40 years\u002F≥40 years) and embryo stage (cleavage stage\u002Fblastocyst) using stratified block randomization.\n* Undergo the first or second frozen-thawed embryo transfer cycle, with transferred embryos meeting the quality criteria (cleavage-stage embryos: Grade I, Grade II, or CP and above; blastocysts: 4BC\u002FCB and above).\n* Receive embryo vitrification and warming after routine fertilization and culture; LAH Group will undergo LAH (thinning zona pellucida for cleavage-stage embryos, removing 1\u002F4-1\u002F3 of zona pellucida circumference for blastocysts) in G2 medium after embryo thawing, while Control Group will not receive assisted hatching.\n* Have endometrial preparation by natural, ovulatory, or hormone replacement cycles as appropriate, and 1-2 viable embryos will be transferred under ultrasound guidance within 3 hours after thawing, followed by routine luteal support after transfer.\n* Complete follow-up at multiple time points: 12-15 days after embryo transfer (serum β-hCG test), 28 days after embryo transfer (transvaginal ultrasound), 12 weeks of gestation (ultrasound), 28 weeks of gestation (ultrasound), and 1 month after delivery (collection of delivery and neonatal information).\n* Provide demographic, clinical, and embryological baseline data, as well as various outcome data during the study period.\n* Undergo regular monitoring of vital signs, laboratory test results, and adverse events, with key prevention and control of specific risks related to LAH such as embryo damage and multiple pregnancy.",[562,563],"Assisted Hatching","Advanced Age",[565,566,567,568,569,570,571],"Laser-Assisted hatching;","Vitrified-warmed embryo transfer","Frozen embryo transfer","Advanced maternal age","Infertility","IVF\u002FICSI","Live birth",{"date":573,"type":40},"2026-03-24",{"date":575,"type":22},"2026-03-16",{"date":501,"type":22},{"name":46,"class":47},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":592,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":75},"100595186","phase-2-taurines-therapeutic-effect-on-acute-radiation-induced-oral-mucositis-and-dermatitis-100595186","NCT07029178","Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","A Randomized Controlled Trial on Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis","Inclusion Criteria:\n\n1. Patients voluntarily joined the study, were informed of the purpose and process of the study, signed the informed consent form, and were willing and able to abide by the study protocol.\n2. Aged 18 to 80, with no gender restrictions.\n3. Patients that require radiotherapy after surgery for oral\u002Foropharyngeal cancer. After evaluation by the radiation oncologist, radiotherapy at 30 sessions \u002F60Gy is planned.\n4. The expected survival period is more than 6 months.\n5. No radiotherapy for the head and neck has been performed in the past, and no other medications that affect the results of this trial have been used. No chemotherapy or immunotherapy was performed within one month before the beginning of the trial.\n\nExclusion criteria:\n\n1. Uncontrollable local or systemic infections of the oral cavity and head and neck.\n2. Active or history of autoimmune diseases; Diseases requiring systemic steroid hormones or immunosuppressive medications.\n3. Bleeding occurred within 3 months before enrollment, including but not limited to: gastrointestinal bleeding caused by gastric fundus or esophageal varices, increased risk of bleeding caused by portal hypertension, active gastrointestinal bleeding, etc. Or there is a risk of major bleeding as assessed by the researcher.\n4. Arterial\u002Fvenous thrombosis that occurred within 6 months prior to the screening, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, etc.\n5. Interstitial pneumonia or active pneumonia with clinical significance, or other respiratory diseases that seriously affect lung function.\n6. History of cardiovascular diseases, including but not limited to: (1) Congestive heart failure (NYHA grade \\> 2); (2) Unstable angina pectoris; (3) Myocardial infarction occurred in the past three months; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention.\n7. Severe endocrine or hematopoietic system diseases (such as diabetes, leukemia, etc.), gastrointestinal obstruction, active bleeding, gastric perforation and other conditions.\n8. Combined with malignant tumors of other organs.\n9. Intractable or refractory epilepsy, with a large amount of pleural effusion, ascites, pericardial effusion, etc. that cannot be controlled by medicines.\n10. History of HIV, syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and\u002For CMV infection within one year before screening, or those with a history of active pulmonary tuberculosis infection for more than one year without regular treatment; active hepatitis B or C. Patients with positive HBsAg or HBcAb can participate in this study if the HBV DNA test is below the lower limit of the normal value detected by the research center; patients with positive HCV antibody can participate in this study if the HCV RNA test is below the lower limit of the normal value detected by the research center.\n11. History of allogeneic bone marrow transplantation or solid organ transplantation.\n12. Have received cell therapy products that have undergone genetic modification or editing in the past.\n13. Have previously used medicines that can cause medication-related osteonecrosis of the jaw.\n14. Have taken drugs containing taurine within one month before randomization in this study.\n15. Allergic to taurine.\n16. Patients who, in addition to radiotherapy, requires chemotherapy or immunotherapy simultaneously.\n17. Mental illness, alcohol abuser, drug user or drug abuser.\n18. Pregnant or lactating women; Women who plans to become pregnant within half a year after treatment.\n19. Poor compliance or other circumstances assessed by the researcher as unsuitable for participation in this clinical study.",{"count":586,"type":22},160,[111],"This is a single-center, double-blind, randomized controlled study. The patients were divided into control group and experimental group, 80 cases each. From the first day of radiotherapy to the end of radiotherapy, the experimental group was treated with 24 grams of taurine granule (containing 4.8 grams of taurine) before each day's radiotherapy. The control group was treated with the same amount of placebo.",[590,591],"Radiation Induced Oral Mucositis","Radiodermatitis",[593,594,595,596,597],"double-blind","randomized controlled trial","taurine","radiodermatitis","radiation-induced oral mucositis",{"date":543,"type":40},{"date":600,"type":40},"2025-11-24",{"date":501,"type":22},{"name":46,"class":47},""]